Related Experiment Video
Updated: Oct 25, 2025
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
Dual Function Antibody Conjugates for Multimodal Imaging and Photoimmunotherapy of Cancer Cells
Mohammad A Saad1, Marvin Xavierselvan2, Hamza A Sharif3
1Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abstract:
Precision imaging, utilizing molecular targeted agents, is an important tool in cancer diagnostics and guiding therapies. While there are limitations associated with single mode imaging probes, multimodal molecular imaging probes enabling target visualization through complementary imaging technologies provides an attractive alternative. However, there are several challenges associated with designing molecular probes carrying contrast agents for complementary multimodal imaging. Here, we propose a dual function antibody conjugate (DFAC) comprising an FDA approved photosensitizer Benzoporphyrin derivative (BPD) and a naphthalocyanine-based photoacoustic dye (SiNc(OH)) for multimodal infrared (IR) imaging. While fluorescence imaging, through BPD, provides sensitivity, complementing it with photoacoustic imaging, through SiNc(OH), provides a depth-resolved spatial resolution much beyond the optical diffusion limits of fluorescence measurements. Through a series of in vitro experiments, we demonstrate the development and utilization of DFACs for multimodal imaging and photodynamic treatment of squamous cell carcinoma (A431) cell line. The proposed DFACs have potential use in precision imaging applications such as guiding tumor resection surgeries and photodynamic treatment of residual microscopic disease thereby minimizing local recurrence. The data demonstrated in this study merits further investigation for its preclinical and clinical translation.
Insights
Researchers developed a dual function antibody conjugate (DFAC) for multimodal cancer imaging. This probe combines fluorescence and photoacoustic imaging for enhanced tumor visualization and targeted photodynamic therapy.
Area of Science:
- Biomedical Engineering
- Molecular Imaging
- Cancer Therapy
Background:
- Precision imaging is crucial for cancer diagnostics and therapy guidance.
- Multimodal imaging probes offer advantages over single-mode probes by combining complementary technologies.
- Designing effective multimodal probes with multiple contrast agents presents significant challenges.
Purpose of the Study:
- To develop and evaluate a dual function antibody conjugate (DFAC) for multimodal infrared (IR) imaging.
- To integrate a photosensitizer (Benzoporphyrin derivative, BPD) and a photoacoustic dye (SiNc(OH)) into a single molecular probe.
- To assess the utility of DFACs for imaging and photodynamic treatment of squamous cell carcinoma.
Main Methods:
- Conjugation of Benzoporphyrin derivative (BPD) and a naphthalocyanine-based photoacoustic dye (SiNc(OH)) onto an antibody.
- In vitro experiments to validate the dual-modal imaging capabilities (fluorescence and photoacoustic).
- Assessment of the DFAC for photodynamic treatment of A431 squamous cell carcinoma cells.
Main Results:
- Successful development of DFACs capable of dual-mode fluorescence and photoacoustic imaging.
- Demonstration of complementary imaging: fluorescence for sensitivity and photoacoustic for depth-resolved spatial resolution.
- In vitro efficacy shown for multimodal imaging and photodynamic treatment of cancer cells.
Conclusions:
- DFACs offer a promising approach for multimodal molecular imaging in precision oncology.
- Potential applications include guiding tumor resection and treating residual disease to minimize recurrence.
- Further preclinical and clinical investigations are warranted for translation.
